| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Dresden University of Technology |
| Information provided by: | Dresden University of Technology |
| ClinicalTrials.gov Identifier: | NCT00180024 |
Purpose
The hypothesis is tested that stimulation with angiotensin II after blockade of the AT1-receptor results in venodilation in human healthy subjects in vivo.
| Condition | Intervention |
|
Healthy Subjects |
Drug: irbesartan (drug) |
| Drug Information available for: | Irbesartan Angiotensin II Angiotensin II, ile(5)- |
| Study Type: | Interventional |
| Study Design: | Educational/Counseling/Training, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Eligibility
| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Germany | |||||
| Institute of Clinical Pharmacology, Medical Faculty, University of Technology | |||||
| Dresden, Germany, 01307 | |||||
| Dresden University of Technology |
| Study Chair: | Wilhelm Kirch, MD | Institute of Clinical Pharmacology |
More Information
| Study ID Numbers: | IKPD 01-02 |
| First Received: | September 9, 2005 |
| Last Updated: | September 9, 2005 |
| ClinicalTrials.gov Identifier: | NCT00180024 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
